Aissa S, Ben Jazia R, Ayachi J, Ben Salem C, Hayouni A, Abdelghani A, Ben Saad H, Boussarsar M
Pulmonology Department, Farhat Hached University Hospital, Sousse, 4000, Tunisia.
Medical Intensive Care Unit, Farhat Hached University Hospital, Sousse, Tunisia.
Contemp Clin Trials Commun. 2016 Jun 18;4:1-8. doi: 10.1016/j.conctc.2016.06.002. eCollection 2016 Dec 15.
Since it was introduced by Noon in 1911, allergen-specific immunotherapy or desensitization has been widely prescribed in the management of allergic diseases. Aimed at the etiology, it represents the only effective treatment for allergy. The basic mechanisms of immunotherapy are becoming better understood and allow us to improve this technique in the future. The sublingual immunotherapy as an alternative to subcutaneous route has been widely studied. Several clinical trials confirmed that sublingual immunotherapy is efficient in reducing allergic respiratory symptoms. The sublingual immunotherapy reduces the risk of developing serious side effects due to desensitization. We performed a literature review in order to remind the mechanisms of action and to demonstrate efficacy and tolerability of the sublingual immunotherapy in the treatment of allergic rhinoconjunctivitis and asthma and its impact on the quality of life.
自1911年由努恩引入以来，变应原特异性免疫疗法或脱敏疗法已被广泛用于过敏性疾病的治疗。针对病因，它是唯一有效的过敏治疗方法。免疫疗法的基本机制正被更好地理解，这使我们能够在未来改进这项技术。舌下免疫疗法作为皮下途径的替代方法已得到广泛研究。多项临床试验证实，舌下免疫疗法在减轻过敏性呼吸道症状方面有效。舌下免疫疗法降低了脱敏引起严重副作用的风险。我们进行了一项文献综述，以回顾其作用机制，并证明舌下免疫疗法在治疗过敏性鼻结膜炎和哮喘中的疗效、耐受性及其对生活质量的影响。
